Israel Englander’s Pacira BioSciences PCRX Stock Holding History

Israel Englander’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-180,300	Closed	-$4.31M	–	6353
2025 Q2	$4.31M	Buy	+180,300	New	+$4.54M	﹤0.01%	3147
2025 Q1	–	Sell	-544,700	Closed	-$10.3M	–	6271
2024 Q4	$10.3M	Buy	+544,700	New	+$9.56M	0.01%	2156
2023 Q2	–	Sell	-11,200	Closed	-$457K	–	6543
2023 Q1	$457K	Buy	+11,200	New	+$446K	﹤0.01%	4661
2017 Q3	–	Sell	-100,000	Closed	-$4.77M	–	3773
2017 Q2	$4.77M	Buy	+100,000	New	+$4.64M	0.01%	1542
2015 Q3	–	Sell	-30,000	Closed	-$2.12M	–	3662
2015 Q2	$2.12M	Buy	+30,000	New	+$2.36M	﹤0.01%	1886

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's PCRX Position: Q2 2026 in Review

Israel Englander increased its Pacira BioSciences (PCRX) stake by 312% in Q2 2026, buying an estimated $4.21M and bringing the position to 235,163 shares worth $5.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

Israel Englander first reported a position in PCRX in Q2 2013 and has held it in 49 quarters since. The position peaked at $70.2M in Q3 2018. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Israel Englander held 235,163 shares of Pacira BioSciences worth $5.97M as of Q2 2026.
Israel Englander bought 178,132 Pacira BioSciences shares in Q2 2026, an estimated $4.21M.
Pacira BioSciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2820 holding.
Israel Englander first reported a position in Pacira BioSciences in Q2 2013 and has held it in 49 quarters since.
Israel Englander's Pacira BioSciences position peaked at $70.2M in Q3 2018.
251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.